Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

OrthoPediatrics Q3 revenue rises, beats estimates

By Reuters News


Overview

  • US pediatric orthopedics device maker's Q3 revenue rose 19% yr/yr, beating analyst expectations

  • Q3 adjusted EBITDA grew yr/yr

  • Company raised full-year 2026 revenue guidance


Outlook

  • OrthoPediatrics raises 2026 revenue guidance to $270 mln-$273 mln from $265 mln-$269 mln

  • Company expects 2026 adjusted EBITDA of about $25 mln and breakeven free cash flow

  • Company expects new product launches to drive financial performance in coming years


Result Drivers

  • TRAUMA & DEFORMITY GROWTH - Co said Q3 revenue growth was mainly driven by global Trauma and Deformity and OPSB product sales

  • HIGHER PROCEDURE VOLUMES - Co attributed Q3 growth to increased procedure volumes

  • PRODUCT EXPANSION - Co cited new and expanded product lines, including Cannulated Screws, PNP Femur, PediPlates, 3P Hip, and OPSB, as drivers of Trauma & Deformity revenue


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$72.70 mln

$68.50 mln (8 Analysts)

Q3 Loss Per Share

$0.25

Q3 Net Loss

$5.93 mln

Q3 Adjusted EBITDA

Miss

$6.90 mln

$8.38 mln (8 Analysts)

Q3 Gross Margin

74.00%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for OrthoPediatrics Corp is $25.00, about 4.1% above its October 26 closing price of $24.02


Reuters Recommended Reads

  • Oct 27 - Repligen Q3 revenue beats estimates on higher demand; lifts outlook

  • Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

  • Oct 27 - Kiniksa Pharmaceuticals Q3 ARCALYST revenue jumps 58%; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.